Literature DB >> 63044

Cyclic nucleotide phosphodiesterase activity of human normal and carcinomatous lung tissue.

P B Curtis-Prior, J R Gibbons, Y H Chan.   

Abstract

The activity of the phosphodiesterase enzyme(s) responsible for the degradation of cylic adenosine monophosphate (CA.M.P.) and cyclic guanosine monophosphate (CG.M.P. (in human normal and carcinomatous lung tissue has been investigated. Enzyme activities were 3-5 times greater in normal than in carcinomatous lung. This is compatible with the known higher concentrations of these cyclic nucleotides in normal tissues. It is suggested that cancer chemotherapy designed to block the phosphodiesterase activity, and thus promote accretion of CA.M.P and CG.M.P., may provide a means of normalising cancerous tissue. Both phosphodiesterase activities in both types of tissue were inhibited by methylxanthines at 10(-3) mol/l, but some enzyme potentiation was observed at lower concentration.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 63044     DOI: 10.1016/s0140-6736(76)91146-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

Authors:  C Gennari; G Francini; M Galli; F Lore
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

2.  Some effects of administration of large doses of vitamin C in patients with skin carcinoma.

Authors:  M Moriarty; S Mulgrew; C Mothersill; J F Malone; M Hatch
Journal:  Ir J Med Sci       Date:  1978-05       Impact factor: 1.568

3.  Effects of several preoperative medications on fat cell lipolysis, and activity of adipose tissue cyclic AMP phosphodiesterase.

Authors:  P B Curtis-Prior; M Jenner; Y H Chan; I McColl
Journal:  Experientia       Date:  1979-11-15

4.  Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.

Authors:  G A Turner; R D Ellis; D Guthrie; A L Latner; J M Monaghan; W M Ross; A W Skillen; R G Wilson
Journal:  J Clin Pathol       Date:  1982-08       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.